History

History of Glenmark Pharmaceuticals Ltd.

The company has not shared this information

Milestones

  • 1977 – 1980
    • 1977 – Incorporated under the companies act as Glenmark Pharmaceuticals Limited
    • 1979 – Launches ‘Candid Cream’, a dermatology product; breaks even and records a small profit.
    • 1980 – Starts its export business
  • 1981 – 1989
    • 1981 – Sales cross INR 1 Crore (INR 10 million)
    • 1988 – Commissions the first manufacturing facility at Nasik, Maharashtra
    • 1984 – Establishes R&D division at Nasik plant
    • 1987 – Launches Ascoril
    • 1989 – Starts operations in Afghanistan, Sri Lanka, Kenya and Mauritius
  • 1990 – 1999
    • 1992 – Expands Nasik Plant and increases installed capacity
    • 1996 – Incorporates Glenmark Exports Private limited, a wholly owned subsidiary, to consolidate its position in international business
    • 1999 – Starts marketing products in Brazil– Commissions R&D facility at Nasik, Maharashtra for developing formulations
  • 2000 – 2010
    • 2000
      • Announces IPO (oversubscribed by a factor of 65)
      • Enters the diabetes segment
      • Acquires 3 brands from Lyka Labs
    • 2001 – Launches first manufacturing facility for APIs in Kurkumbh, Maharashtra
    • 2002 – Acquires an API manufacturing facility from GlaxoSmithKline Pharmaceuticals Ltd. at Ankleshwar, Gujarat
    • 2004
      • Strikes first out-licensing deal for discovery R&D with Forest Laboratories for Oglemilast, its COPD/asthma molecule
      • Acquires Laboratorios Klinger, Brazil together with its ANVISA approved manufacturing facility to expand Latin American operations
      • Commissions manufacturing facility at Goa export to regulated markets, like USA
      • Commissions API manufacturing facility in Mohol, Maharashtra
    • 2005
      • Launches front–end commercial sales in the US
      • Enters into collaborative agreement on Oglemilast with Teijin Pharma for the Japan region
      • Announces collaborative agreement with Napo Pharmaceuticals Inc. for anti–diarrheal compound, Crofelemer with rights in nearly 140 countries
      • Acquires Servycal S.A, a marketing company in Argentina (oncology)
      • Acquires Bouwer Bartlett Pty., Ltd., a sales and marketing company in South Africa
      • Commissions a new manufacturing facility at Baddi, Himachal Pradesh
    • 2006
      • Signs another outlicensing deal in discovery R&D with Merck KGaA, Germany for its diabetes molecule, Melogliptin and receives USD 31 million as upfront payment
      • Receives milestone payment from Forest Laboratories Inc. for successful completion of Phase I trials
      • Commissions R&D facility for NBE research in Switzerland
    • 2007
      • Acquires Medicamenta, a marketing and manufacturing company in the Czech Republic
      • Concludes deal with Paul Capital to license and market generic drugs for the US market via US subsidiary
      • Outlicenses GRC 6211 molecule for pain treatment to Eli Lily and receives USD 45 million as upfront payment
      • Wins Emerging Company of The Year 2007 at The Economic Times Awards for Corporate Excellence
      • Receives MHRA, UK approval for its semi-solid manufacturing plant at Baddi
    • 2008
      • Receives fast-track status from the USFDA for Crofelemer
      • Named “Best Pharma Company in the World – SME” and the “Best Company in Emerging Markets” at the SCRIP Awards 2008 in London
      • Sets up clinical R&D facility in Oxford, UK (India’s first)
      • Receives USD 15 million as milestone payment from Forest for Oglemilast, GRC 3886
      • Reorganizes business and incorporates Glenmark Generics Limited (GGL) as a subsidiary of Glenmark Pharmaceuticals Limited
      • Receives USFDA approval for semi–solids manufacturing plant at Baddi, Himachal Pradesh
    • 2009
      • Commissions formulations manufacturing facility at Nalagarh, Himachal Pradesh
      • Commissions first exclusive R&D Center at Taloja, Maharashtra, India
    • 2000 – 2010
      • Launches ‘Prasugrel’ – a revolutionary new anti-platelet drug for the managing Acute Coronary Syndrome with PCI (Percutaneous Coronary Intervention) for the first time in India
      • Signs license agreement with Sanofi-Aventis allowing the latter to develop and commercialize novel agents to treat chronic pain
      • Enters into an exclusive licensing agreement with Par Pharmaceuticals, USA to market Ezetimibe
      • Announces the discovery of a novel chemical entity ‘GRC 17536’
      • Receives the final approval for Pramipexole Dihydrochloride tablets from the USFDA
      • Wins the Frost and Sullivan award for ‘Indian Innovator Pharmaceutical Company of the Year’ in October 2010
      • Receives the ‘Silver Patent Award’ for the year 2009 – 2010 from Pharmaexcil for commendable contribution in NCE / Drug Discovery patent category
      • Successfuly completes Phase 3 trials for Crofelemer, a first-in-class anti-diarrhoeal molecule and prepares for launch in 140 countries
    • 2011
      • Wins Two Prestigious Global Recognitions at SCRIP Awards 2011 – ‘Best Company in Emerging Markets’ and ‘Best Overall Pipeline’
      • Out-Licenses Novel Monoclonal Antibody, GBR 500, to Sanofi
    • 2012
      • Founder & Chairman Emeritus, Mr. Gracias Saldanha, passes away peacefully in Mumbai
      • Mr. Glenn Saldanha, Chairman & Managing Director, honored with the ‘Swiss Ambassador’s Award for Exceptional Innovation’ by the Government of Switzerland
      • Enters into an options agreement with Forest Laboratories, Inc. to develop novel mPGES-1 inhibitors for treating chronic inflammatory conditions, including pain

Source: https://www.brandindiapharma.in/pharmaceutical-companies-india/glenmark-pharmaceuticals-ltd

ˆ Back To Top